CBIO GLYCOMIMETICS INC

Nasdaq glycomimetics.com


$ 11.17 $ 0.90 (8.66 %)    

Wednesday, 15-Oct-2025 17:18:52 EDT
QQQ $ 602.50 $ 4.22 (0.71 %)
DIA $ 463.06 $ 0.00 (0 %)
SPY $ 665.00 $ 2.94 (0.44 %)
TLT $ 90.75 $ -0.20 (-0.22 %)
GLD $ 387.60 $ 6.60 (1.73 %)
$ 11.29
$ 10.52
$ 10.00 x 115
$ 11.90 x 100
$ 10.52 - $ 11.83
$ 9.81 - $ 63.00
91,170
na
156.85M
$ 1.68
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-31-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 02-13-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-27-2024 12-31-2023 10-K
8 11-03-2023 09-30-2023 10-Q
9 08-02-2023 06-30-2023 10-Q
10 05-03-2023 03-31-2023 10-Q
11 03-29-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 04-28-2022 03-31-2022 10-Q
15 03-03-2022 12-31-2021 10-K
16 11-02-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-03-2021 03-31-2021 10-Q
19 03-02-2021 12-31-2020 10-K
20 11-06-2020 09-30-2020 10-Q
21 07-31-2020 06-30-2020 10-Q
22 05-01-2020 03-31-2020 10-Q
23 02-28-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
25 08-01-2019 06-30-2019 10-Q
26 05-02-2019 03-31-2019 10-Q
27 03-06-2019 12-31-2018 10-K
28 11-02-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-03-2018 03-31-2018 10-Q
31 03-06-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-03-2017 06-30-2017 10-Q
34 05-08-2017 03-31-2017 10-Q
35 03-01-2017 12-31-2016 10-K
36 11-04-2016 09-30-2016 10-Q
37 08-04-2016 06-30-2016 10-Q
38 05-04-2016 03-31-2016 10-Q
39 02-29-2016 12-31-2015 10-K
40 11-12-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-crescent-biopharma-maintains-25-price-target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Crescent Biopharma (NASDAQ:CBIO) with a Buy and maintains $25 ...

 jefferies-initiates-coverage-on-crescent-biopharma-with-buy-rating-announces-price-target-of-26

Jefferies analyst Akash Tewari initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price ...

 hc-wainwright--co-initiates-coverage-on-crescent-biopharma-with-buy-rating-announces-price-target-of-25

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating ...

 wedbush-initiates-coverage-on-crescent-biopharma-with-outperform-rating-announces-price-target-of-27

Wedbush analyst Robert Driscoll initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Outperform rating and announce...

 stifel-initiates-coverage-on-crescent-biopharma-with-buy-rating-announces-price-target-of-28

Stifel analyst Stephen Willey initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price T...

 lifesci-capital-initiates-coverage-on-crescent-biopharma-with-outperform-rating-announces-price-target-of-22

LifeSci Capital analyst Charles Zhu initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Outperform rating and anno...

 us-stocks-likely-to-open-higher-despite-trumps-unconditional-surrender-call-all-eyes-on-powell-as-experts-predict-inflation-will-limit-feds-rate-cut-capacity

U.S. futures were higher on Wednesday as oil futures tumbled after Donald Trump called for an "Unconditional Surrender"...

 catalyst-biosciences-announces-completion-of-business-combination-with-beijing-continent-pharmaceuticals-and-implementation-of-name-change-and-1-for-15-reverse-stock-split-company-will-operate-as-gyre-therapeutics-inc-under-trading-symbol-gyre

The combined company will operate as "Gyre Therapeutics, Inc." with its common stock traded on Nasdaq under trading sym...

 why-owens-corning-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed bus...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION